SEC Company Response from Outlook Therapeutics, Inc. (OTLK) (CIK 0001649989) (OTLK) — Mar 5, 2025
Outlook Therapeutics, Inc. (OTLK) (CIK 0001649989)
Date: March 5, 2025 · CIK: 0001649989 · Accession: 0001558370-25-002216
AI Filing Summary & Sentiment
File numbers found in text: 333-285438
Letter
OUTLOOK THERAPEUTICS, INC.
111 S. Wood Avenue
Unit #100
Iselin, New Jersey 08830
(609) 619-3990
March 5, 2025
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re:
Outlook Therapeutics, Inc.
Registration Statement on Form S-3
Filed February 28, 2025
File No. 333-285438
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-3 (File No. 333-285438) (the “Registration Statement”) to become effective on Friday, March 7, 2025, at 4:00 p.m., Eastern Time, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the “Staff”). The Registrant hereby authorizes David N. Braus and Robert-Joseph Davis of Outlook Therapeutics as well as Yvan-Claude Pierre of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Robert-Joseph Davis of Outlook Therapeutics (717) 877-3197. In the case of his absence, please contact Yvan-Claude Pierre of Cooley LLP, outside counsel to the Registrant, at (212) 479-6721, or Courtney Tygesson of Cooley LLP at (312) 881-6680.
Very truly yours,
Show Raw Text
CORRESP 1 filename1.htm OUTLOOK THERAPEUTICS, INC. 111 S. Wood Avenue Unit #100 Iselin, New Jersey 08830 (609) 619-3990 March 5, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Outlook Therapeutics, Inc. Registration Statement on Form S-3 Filed February 28, 2025 File No. 333-285438 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-3 (File No. 333-285438) (the “Registration Statement”) to become effective on Friday, March 7, 2025, at 4:00 p.m., Eastern Time, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the “Staff”). The Registrant hereby authorizes David N. Braus and Robert-Joseph Davis of Outlook Therapeutics as well as Yvan-Claude Pierre of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Robert-Joseph Davis of Outlook Therapeutics (717) 877-3197. In the case of his absence, please contact Yvan-Claude Pierre of Cooley LLP, outside counsel to the Registrant, at (212) 479-6721, or Courtney Tygesson of Cooley LLP at (312) 881-6680. Very truly yours, OUTLOOK THERAPEUTICS, INC. By: /s/ Lawrence A. Kenyon Name: Lawrence A. Kenyon Title: Chief Financial Officer and Interim Chief Executive Officer cc: Yvan-Claude Pierre, Cooley LLP Courtney Tygesson, Cooley LLP David N. Braus, Outlook Therapeutics, Inc Robert-Joseph Davis, Outlook Therapeutics, Inc